Product Name

  • Name

    4-Acetamidophenol

  • EINECS 203-157-5
  • CAS No. 103-90-2
  • Article Data344
  • CAS DataBase
  • Density 1.249 g/cm3
  • Solubility 14 g/L (20 °C) in water
  • Melting Point 168-172 °C(lit.)
  • Formula C8H9NO2
  • Boiling Point 387.8 °C at 760 mmHg
  • Molecular Weight 151.165
  • Flash Point 188.4 °C
  • Transport Information
  • Appearance White crystalline powder
  • Safety 26-36-61-37/39-22
  • Risk Codes 22-36/37/38-52/53-36/38-40
  • Molecular Structure Molecular Structure of 103-90-2 (4-Acetamidophenol)
  • Hazard Symbols HarmfulXn
  • Synonyms Acetamide,N-(4-hydroxyphenyl)-;Acetanilide,4'-hydroxy- (7CI,8CI);4-(Acetylamino)phenol;4-(N-Acetylamino)phenol;4-Acetamidophenol;4-Acetaminophenol;4-Hydroxyacetanilide;4'-Hydroxyacetanilide;Alpiny;Alvedon;Anhiba;Apamid;Apamide;Banesin;Ben-u-ron;Bickie-mol;Biocetamol;Cetadol;Clixodyne;Daphalgan;Datril;Dirox;Enelfa;Eu-Med;Exdol;Gattaphen T;Homoolan;Jin Gang;Korum;Lestemp;Liquagesic;Lonarid;Lyteca;Lyteca Syrup;Minoset;Minoset Plus;Momentum;Multin;N-(4-Hydroxyphenyl)acetamide;N-Acetyl-4-aminophenol;N-Acetyl-4-hydroxyaniline;Pacemo;Pacemol;Panadol;Panadol Actifast;Panadol Extend;Panaleve;Panasorb;Panets;Panodil;Paracetamol;Paracetamol DC;Paracetamole;Parageniol;Paralen;Paramol;Paraspen;Parelan;Parmol;Pasolind N;Pedric;k*e*t*a*m*i*n*e ,kush available;
  • PSA 49.33000
  • LogP 1.42360

Synthetic route

4-Hydroxyacetophenone
99-93-4

4-Hydroxyacetophenone

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
With hydroxylamine hydrochloride In acetonitrile at 110℃; for 1h; Solvent; Time; chemoselective reaction;100%
With hydroxylamine hydrochloride; tetrachlorosilane at 160℃; for 0.0583333h; microwave irradiation;92%
With mesitylenesulfonylhydroxylamine In acetonitrile at 20℃; for 6h;92%
acetic anhydride
108-24-7

acetic anhydride

4-amino-phenol
123-30-8

4-amino-phenol

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
With sodium dodecyl-sulfate In water99%
With silica gel for 0.5h; Time; Milling;99%
With sulfuric acid supported on poly(4-vinylpyridine) (P4VP) In dichloromethane at 20℃; for 1.25h;98%
4-acetoxyacetanilide
2623-33-8

4-acetoxyacetanilide

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
With ammonium acetate In methanol at 20℃; for 4.5h;99%
With ytterbium(III) triflate In isopropyl alcohol for 15h; Deacetylation; Heating;96%
With sodium perborate In methanol at 25℃; for 0.5h;90%
4-hydroxyacetophenone oxime
34523-34-7

4-hydroxyacetophenone oxime

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
With 1,1,1,3',3',3'-hexafluoro-propanol; perfluoropinacol; 2-methoxycarbonylphenylboronic acid In nitromethane at 20℃; for 24h; Beckmann Rearrangement; chemoselective reaction;99%
With 2,2-dichloro-1,3-dicyclohexylimidazolidine-4,5-dione In acetonitrile at 80℃; for 0.333333h; Inert atmosphere; Schlenk technique; Green chemistry;98%
With carbon tetrabromide; Eosin Y; N,N-dimethyl-formamide In acetonitrile at 20℃; for 14h; Beckmann Rearrangement; Irradiation; Inert atmosphere; Green chemistry;96%
4-nitro-phenol
100-02-7

4-nitro-phenol

acetic acid
64-19-7

acetic acid

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
at 80 - 130℃; Temperature;98%
With sodium sulfite for 16h; Reflux;83%
With Methyl formate; dodecacarbonyl-triangulo-triruthenium at 180℃; for 8h;92 % Chromat.
With hydrogen at 100℃; under 760.051 Torr; for 24h; Sealed tube;82 %Chromat.
With platinum; hydrogen at 100℃; for 24h;
p-nitrosophenol
104-91-6

p-nitrosophenol

acetic acid
64-19-7

acetic acid

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
at 80 - 130℃;98%
acetic anhydride
108-24-7

acetic anhydride

4-amino-benzoic acid
150-13-0

4-amino-benzoic acid

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
With acetic acid at 80℃; for 1h; Temperature;97.13%
4-amino-phenol
123-30-8

4-amino-phenol

acetylacetone
123-54-6

acetylacetone

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
With dihydrogen peroxide In water at 25℃; for 8h; Green chemistry;97%
(4-acetylaminophenyl)boronic acid
101251-09-6

(4-acetylaminophenyl)boronic acid

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
With water; dihydrogen peroxide In ethanol at 20℃; for 0.0166667h; Green chemistry;97%
With Oxone; potassium phosphate; 2-(biphenyl-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane In water at 70℃; for 1h; chemoselective reaction;
acetamide
60-35-5

acetamide

4-amino-phenol
123-30-8

4-amino-phenol

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
With dipotassium peroxodisulfate In water at 100℃; for 0.166667h; Microwave irradiation; Green chemistry;96%
at 150℃; for 72h; Inert atmosphere; Sealed tube; Green chemistry;96%
With air at 150℃; for 72h; Sealed tube;96%
4-nitro-phenol
100-02-7

4-nitro-phenol

acetic anhydride
108-24-7

acetic anhydride

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
With sodium tetrahydroborate; chloro-trimethyl-silane In methanol; water at 20℃; for 0.333333h; Reagent/catalyst; Irradiation;95%
With hydrogen In para-xylene at 130℃; under 750.075 Torr; for 24h; chemoselective reaction;95%
With samarium; acetic acid In methanol at 20℃; for 1.5h;80%
Stage #1: 4-nitro-phenol With sodium tetrahydroborate at 20℃; for 0.5h; Green chemistry;
Stage #2: acetic anhydride at 120℃; for 1h; Catalytic behavior; Green chemistry;
78%
With acetic acid; platinum Hydrogenation;
4-amino-phenol
123-30-8

4-amino-phenol

1-acetyl-1H-1,2,3-triazolo<4,5-b>pyridine
107866-54-6

1-acetyl-1H-1,2,3-triazolo<4,5-b>pyridine

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
In tetrahydrofuran for 1h; Ambient temperature;95%
4-amino-phenol
123-30-8

4-amino-phenol

2-acetyl-4,5-dichloropyridazin-3(2H)-one
155164-63-9

2-acetyl-4,5-dichloropyridazin-3(2H)-one

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
In tetrahydrofuran at 17℃; for 0.2h;95%
(E)-1-(4-hydroxyphenyl)ethan-1-one oxime
198712-64-0

(E)-1-(4-hydroxyphenyl)ethan-1-one oxime

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
With 2,2-dichloro-1,3-dicyclohexylimidazolidine-4,5-dione In acetonitrile at 80℃; for 0.333333h; Beckmann Rearrangement; Inert atmosphere; Schlenk technique;95%
With 1,1,1,3',3',3'-hexafluoro-propanol; tetrabutylammonium tetrafluoroborate; water In 1,2-dichloro-ethane at 20℃; for 0.533333h; Beckmann Rearrangement; Electrochemical reaction;92%
With cerium(III) chloride; silica gel; sodium iodide for 0.133333h; Beckmann rearrangement; microwave irradiation;82%
With 1,3,5-trichloro-2,4,6-triazine In N,N-dimethyl-formamide at 20℃; for 6h; Beckmann rearrangement;80%
4-methoxyacetanilide
51-66-1

4-methoxyacetanilide

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
With boron tribromide In dichloromethane at 0℃; for 1.5h; Inert atmosphere;95%
With boron tribromide In dichloromethane at 20℃; Inert atmosphere;68%
With boron tribromide In dichloromethane Cooling with ice; Inert atmosphere;68%
With 1H-imidazole; iron (III) meso-tetrakis (2,6-dichlorophenylporphyrin-β-octabromo)chloride; 3-chloro-benzenecarboperoxoic acid In isopropyl alcohol; acetonitrile at 20℃; for 24h; Reagent/catalyst;19.2%
N-[4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]acetamide
103202-04-6

N-[4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]acetamide

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
With potassium hydrogen difluoride In methanol at 20℃; for 2h;95%
With cerium (IV) sulfate tetrahydrate In methanol at 130℃; for 0.333333h; Microwave irradiation;94%
With aluminium(III) chloride hexahydrate In methanol at 100℃; for 0.25h; Solvent; Temperature; Microwave irradiation; Sealed tube; chemoselective reaction;90%
N,N-dimethyl acetamide
127-19-5

N,N-dimethyl acetamide

4-amino-phenol
123-30-8

4-amino-phenol

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
With 1H-imidazole; nickel oxinate at 150℃;95%
With 1,2,4-Triazole; 8-quinolinol; copper(II) choride dihydrate at 150℃;91%
With Imidazole hydrochloride at 150℃; for 4h; Sealed tube;89%
With ammonium iodide at 125℃; for 17h;29%
acetic acid
64-19-7

acetic acid

4-nitrophenol sodium salt
824-78-2

4-nitrophenol sodium salt

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
at 80 - 130℃;95%
4-amino-phenol
123-30-8

4-amino-phenol

acetic acid
64-19-7

acetic acid

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
With magnesia In neat (no solvent) at 70℃; for 0.166667h; Green chemistry; chemoselective reaction;93%
at 60 - 120℃; for 11h; Product distribution / selectivity;91.6%
With Starbon-400-SO3H at 130℃; for 0.05h; Microwave irradiation; chemoselective reaction;89%
4-amino-phenol
123-30-8

4-amino-phenol

acetyl chloride
75-36-5

acetyl chloride

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
With calcium oxide In 2-methyltetrahydrofuran at 20℃; for 4h; Green chemistry; chemoselective reaction;93%
With triethylamine In dichloromethane at 0 - 20℃; for 3.16667h; Inert atmosphere;83%
With silica gel at 20℃; for 2.5h; Green chemistry; chemoselective reaction;82%
3-((1-acetyl-1H-benzo[d][1,2,3]triazol-5-yl)methyl)-1,2-dimethyl-1H-pyrazol-2-ium hexauorophosphate

3-((1-acetyl-1H-benzo[d][1,2,3]triazol-5-yl)methyl)-1,2-dimethyl-1H-pyrazol-2-ium hexauorophosphate

4-amino-phenol
123-30-8

4-amino-phenol

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
With dmap In water at 100℃; for 0.25h; Microwave irradiation; Green chemistry;93%
4-amino-phenol
123-30-8

4-amino-phenol

acetonitrile
75-05-8

acetonitrile

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
With aluminum oxide at 200℃; under 37503.8 Torr; for 0.45h; Sonication; Green chemistry;93%
With tert.-butylnitrite; trifluorormethanesulfonic acid; water at 60℃; for 24h;42%
4-amino-phenol
123-30-8

4-amino-phenol

thioacetic acid
507-09-5

thioacetic acid

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
With Fe3O4(at)Chit-TCT-Salen-Cu(II) In water at 20℃; for 0.0833333h; chemoselective reaction;92%
With copper(II)-grafted guanidine acetic acid-modified magnetite nanoparticles In water at 20℃; for 0.0833333h; Green chemistry; chemoselective reaction;91%
With 10-methyl-9-(2,4,6-trimethylphenyl) acridinium tetrafluoroborate In acetonitrile at 20℃; for 5h; Irradiation;78%
With 10-methyl-9-(2,4,6-trimethylphenyl) acridinium tetrafluoroborate In acetonitrile at 20℃; for 5h; Irradiation;78%
With copper(ll) sulfate pentahydrate In methanol at 20℃; for 0.0833333h;75%
4-amino-phenol
123-30-8

4-amino-phenol

N-acetyl-1,3-oxazol-2-one
60759-49-1

N-acetyl-1,3-oxazol-2-one

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
In tetrahydrofuran for 7h; Ambient temperature;90%
4-acetamidophenyl allyl ether
6622-73-7

4-acetamidophenyl allyl ether

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
With ammonium formate; palladium on activated charcoal In methanol for 1h; Heating;90%
With potassium hydroxide; palladium on activated charcoal In methanol at 20℃; for 48h;86%
With potassium hydroxide In methanol at 20℃; for 48h;86%
With iodine In dimethyl sulfoxide at 130℃; for 0.5h;83%
N,N’-(1,2-ethanediylidene)bis-hydroxyphenylamine
24764-93-0

N,N’-(1,2-ethanediylidene)bis-hydroxyphenylamine

acetic anhydride
108-24-7

acetic anhydride

A

Glyoxal
131543-46-9

Glyoxal

B

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
With water; sodium dodecyl-sulfate at 25 - 30℃; for 0.166667h;A 85%
B 90%
4-Hydroxyacetophenone
99-93-4

4-Hydroxyacetophenone

A

4-acetaminophenol
103-90-2

4-acetaminophenol

B

4-hydroxyacetophenone oxime
34523-34-7

4-hydroxyacetophenone oxime

Conditions
ConditionsYield
With hydroxylamine hydrochloride In acetonitrile at 70℃; for 15h;A 90%
B 8%
With hydroxylamine hydrochloride at 70 - 110℃; Solvent; chemoselective reaction;
Acetanilid
103-84-4

Acetanilid

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
With formic acid; boron trifluoride diethyl etherate; bis-[(trifluoroacetoxy)iodo]benzene at 20℃; for 0.5h; regioselective reaction;89%
With trifluoroacetic acid In ethanol; water at 20℃; for 3h; Electrochemical reaction; Green chemistry; regioselective reaction;32%
With 1H-imidazole; iron (III) meso-tetrakis (2,6-dichlorophenylporphyrin-β-octabromo)chloride; 3-chloro-benzenecarboperoxoic acid In isopropyl alcohol; acetonitrile at 20℃; for 24h; Reagent/catalyst;19.2%
4-amino-phenol
123-30-8

4-amino-phenol

3-acetylthiazolidine-2-thione
76397-53-0

3-acetylthiazolidine-2-thione

4-acetaminophenol
103-90-2

4-acetaminophenol

Conditions
ConditionsYield
In dichloromethane at 25℃; for 3h;88%
formaldehyd
50-00-0

formaldehyd

4-acetaminophenol
103-90-2

4-acetaminophenol

diethylamine
109-89-7

diethylamine

N-{3-[(diethylamino)methyl]-4-hydroxyphenyl}acetamide
121-78-8

N-{3-[(diethylamino)methyl]-4-hydroxyphenyl}acetamide

Conditions
ConditionsYield
In ethanol at 80℃; for 1.5h; Microwave irradiation;100%
In ethanol for 12h; Heating;80%
In ethanol at 80℃; for 1h; Microwave irradiation;77%
4-acetaminophenol
103-90-2

4-acetaminophenol

4-amino-phenol
123-30-8

4-amino-phenol

Conditions
ConditionsYield
With ammonium bromide; ethylenediamine at 70℃; for 5h; Reagent/catalyst; Temperature; Microwave irradiation;100%
With ammonium bromide; ethylenediamine at 70℃; for 5h; Microwave irradiation; Inert atmosphere; neat (no solvent);99%
With ammonium iodide; hydrazine hydrate at 50℃; for 12h; Inert atmosphere; Sealed tube;97%
4-acetaminophenol
103-90-2

4-acetaminophenol

S-tert-butyl cyclohexylcarbamoylthioacetate
339274-36-1

S-tert-butyl cyclohexylcarbamoylthioacetate

N-cyclohexyl-malonamic acid 4-acetylamino-phenyl ester

N-cyclohexyl-malonamic acid 4-acetylamino-phenyl ester

Conditions
ConditionsYield
With silver trifluoroacetate In tetrahydrofuran at 20℃;100%
4-acetaminophenol
103-90-2

4-acetaminophenol

methyl iodide
74-88-4

methyl iodide

4-methoxyacetanilide
51-66-1

4-methoxyacetanilide

Conditions
ConditionsYield
With potassium carbonate In acetone at 65℃; for 24h; Inert atmosphere;100%
With sodium ethanolate
4-acetaminophenol
103-90-2

4-acetaminophenol

tert-butyldimethylsilyl chloride
18162-48-6

tert-butyldimethylsilyl chloride

N-[4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]acetamide
103202-04-6

N-[4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]acetamide

Conditions
ConditionsYield
With ferric hydrogen sulphate; triethylamine at 20℃; for 60h; Inert atmosphere; chemoselective reaction;100%
With 1H-imidazole In tetrahydrofuran for 16h; Schlenk technique; Inert atmosphere;97%
With 1H-imidazole Sealed tube; Inert atmosphere;89%
5-nitro-2-fluorotoluene
455-88-9

5-nitro-2-fluorotoluene

4-acetaminophenol
103-90-2

4-acetaminophenol

C15H14N2O4

C15H14N2O4

Conditions
ConditionsYield
Stage #1: 4-acetaminophenol With potassium carbonate In N,N-dimethyl-formamide at 20℃; for 1h;
Stage #2: 5-nitro-2-fluorotoluene In N,N-dimethyl-formamide at 140℃; for 5h; Solvent;
99.5%
4-acetaminophenol
103-90-2

4-acetaminophenol

p-toluenesulfonyl chloride
98-59-9

p-toluenesulfonyl chloride

toluene-4-sulfonic acid 4-acetylaminophenyl ester
301337-51-9

toluene-4-sulfonic acid 4-acetylaminophenyl ester

Conditions
ConditionsYield
With potassium carbonate In tetrahydrofuran; water at 0 - 20℃; for 2h; Green chemistry;99%
With triethylamine In dichloromethane for 16h;62%
With sodium carbonate
With pyridine In dichloromethane at 20℃;
iodomethane-d3
865-50-9

iodomethane-d3

4-acetaminophenol
103-90-2

4-acetaminophenol

N-(4-methoxy-d3-phenyl)acetamide
54536-22-0

N-(4-methoxy-d3-phenyl)acetamide

Conditions
ConditionsYield
With potassium carbonate In acetone at 20 - 25℃; for 24h;99%
With potassium carbonate In acetone at 20 - 25℃; for 24h;99%
With potassium carbonate In acetone at 20℃;479 mg
4-acetaminophenol
103-90-2

4-acetaminophenol

1-Bromopinacolon
5469-26-1

1-Bromopinacolon

N-(4-(3,3-dimethyl-2-oxobutoxy)phenyl)acetamide

N-(4-(3,3-dimethyl-2-oxobutoxy)phenyl)acetamide

Conditions
ConditionsYield
With potassium carbonate In acetone at 70℃; for 16h;99%
1-(13)C-ethyl iodide
75560-39-3

1-(13)C-ethyl iodide

4-acetaminophenol
103-90-2

4-acetaminophenol

N-4-((1-13C)Ethoxy)phenylacetamide
72156-72-0

N-4-((1-13C)Ethoxy)phenylacetamide

Conditions
ConditionsYield
With potassium carbonate In acetone for 60h;98.6%
1-bromo-octane
111-83-1

1-bromo-octane

4-acetaminophenol
103-90-2

4-acetaminophenol

N-(4-(octyloxy)phenyl)acetamide
55792-63-7

N-(4-(octyloxy)phenyl)acetamide

Conditions
ConditionsYield
With potassium hydroxide In ethanol for 12h; Reflux;98%
With potassium carbonate In butanone at 70℃; for 18h; Williamson Ether Synthesis;91%
With potassium carbonate In acetone for 48h; Heating;80%
4-acetaminophenol
103-90-2

4-acetaminophenol

N-(4-hydroxy-3-nitrophenyl)acetamide
51288-37-0

N-(4-hydroxy-3-nitrophenyl)acetamide

Conditions
ConditionsYield
With silica gel; citric acid; sodium nitrite In hexane at 20℃; for 2.25h;98%
With Nitrite In aq. acetate buffer at 25℃; pH=5; Electrochemical reaction; Green chemistry; regioselective reaction;85%
With sulfuric acid; guanidine nitrate In water at 0 - 5℃; Inert atmosphere;84%
4-acetaminophenol
103-90-2

4-acetaminophenol

1-dodecylbromide
143-15-7

1-dodecylbromide

N-(4-(dodecyloxy)phenyl)acetamide
95705-65-0

N-(4-(dodecyloxy)phenyl)acetamide

Conditions
ConditionsYield
With potassium carbonate In butanone for 24h; Reflux;98%
With potassium carbonate In butanone at 70℃; for 18h; Williamson Ether Synthesis;86%
With potassium carbonate In acetone for 18h; Heating;72%
4-acetaminophenol
103-90-2

4-acetaminophenol

acetyl chloride
75-36-5

acetyl chloride

4-acetoxyacetanilide
2623-33-8

4-acetoxyacetanilide

Conditions
ConditionsYield
With triethylamine In dichloromethane at 0℃; Inert atmosphere;98%
With triethylamine In dichloromethane at 0℃; for 2h;97%
4-acetaminophenol
103-90-2

4-acetaminophenol

para-nitrophenyl bromide
586-78-7

para-nitrophenyl bromide

4-nitrophenyl 4'-acetamidophenyl ether
2687-40-3

4-nitrophenyl 4'-acetamidophenyl ether

Conditions
ConditionsYield
With copper(l) iodide; 2-carbomethoxy-3-hydroxyquinoxaline-di-N-oxide; caesium carbonate In N,N-dimethyl-formamide at 110℃; for 11h; Schlenk technique; Inert atmosphere;98%
4-acetaminophenol
103-90-2

4-acetaminophenol

benzyl bromide
100-39-0

benzyl bromide

N-[4-(benzyloxy)phenyl]acetamide
41927-14-4

N-[4-(benzyloxy)phenyl]acetamide

Conditions
ConditionsYield
With caesium carbonate In N,N-dimethyl-formamide at 40℃;98%
With potassium carbonate In acetone for 4h; Reflux;97%
With potassium carbonate In acetone at 65℃; for 4h; Inert atmosphere;97%
With potassium carbonate In acetonitrile at 70℃;
4-acetaminophenol
103-90-2

4-acetaminophenol

propargyl bromide
106-96-7

propargyl bromide

N-(4-(prop-2-yn-1-yloxy)phenyl)acetamide
26557-77-7

N-(4-(prop-2-yn-1-yloxy)phenyl)acetamide

Conditions
ConditionsYield
With caesium carbonate In acetonitrile98%
With sodium hydride In N,N-dimethyl-formamide at 0 - 20℃; for 2h;95%
Stage #1: 4-acetaminophenol With sodium hydroxide In water at 70℃;
Stage #2: propargyl bromide With tetrabutylammomium bromide In water; toluene at 70℃; for 24h;
94%
4-acetaminophenol
103-90-2

4-acetaminophenol

2,2-dichloro-4,4,6,6-bis[spiro(2',2''-dioxy-1'',1''-biphenyl)]cyclotriphosphazene
128175-80-4

2,2-dichloro-4,4,6,6-bis[spiro(2',2''-dioxy-1'',1''-biphenyl)]cyclotriphosphazene

C40H32N5O8P3
165899-64-9

C40H32N5O8P3

Conditions
ConditionsYield
With potassium carbonate In acetone for 48h; Reflux; Inert atmosphere;98%
triethylsilyl chloride
994-30-9

triethylsilyl chloride

4-acetaminophenol
103-90-2

4-acetaminophenol

C14H23NO2Si
929259-42-7

C14H23NO2Si

Conditions
ConditionsYield
With ferric hydrogen sulphate; triethylamine at 20℃; for 60h; Inert atmosphere; chemoselective reaction;98%
With triethylamine at 20℃; Inert atmosphere;80%
4-acetaminophenol
103-90-2

4-acetaminophenol

4-acetamidophenyl sulfurofluoridate
16704-37-3

4-acetamidophenyl sulfurofluoridate

Conditions
ConditionsYield
With fluorosulfonyl fluoride; N-ethyl-N,N-diisopropylamine In acetonitrile at 20℃; for 18h;98%
Stage #1: 4-acetaminophenol With triethylamine In acetonitrile at 20℃; for 0.166667h;
Stage #2: With 1-(fluorosulfuryl)-2,3-dimethyl-1H-imidazol-3-ium trifluoromethanesulfonate In acetonitrile for 1h;
98%
Stage #1: 4-acetaminophenol With triethylamine In acetonitrile at 20℃; for 0.166667h;
Stage #2: With 1-(fluorosulfuryl)-2,3-dimethyl-1H-imidazol-3-ium trifluoromethanesulfonate In acetonitrile for 1h; Inert atmosphere;
98%
4-acetaminophenol
103-90-2

4-acetaminophenol

1,1'-spiro-<2,2'-dioxybiphenyl-1,1'>-3,3',5,5'-tetrachloro-2,4,6,1λ5,3λ5,5λ5-triazatriphosphorine
128175-79-1

1,1'-spiro-<2,2'-dioxybiphenyl-1,1'>-3,3',5,5'-tetrachloro-2,4,6,1λ5,3λ5,5λ5-triazatriphosphorine

C44H40N7O10P3
1331732-22-9

C44H40N7O10P3

Conditions
ConditionsYield
With potassium carbonate In acetone for 48h; Reflux; Inert atmosphere;97%

Acetaminophen History

Harmon Northrop Morse had already synthesized paracetamol at Johns Hopkins University via the reduction of p-nitrophenol with tin in glacial acetic acid in 1877, but it wasn't until 1887 that clinical pharmacologist Joseph von Mering tried paracetamol on patients.
In 1893, von Mering published a paper reporting on the clinical results of paracetamol with phenacetin, another aniline derivative. Von Mering claimed that, unlike phenacetin, paracetamol had a slight tendency to produce methemoglobinemia.
Paracetamol was then quickly discarded in favor of phenacetin. The sales of phenacetin established Bayer as a leading pharmaceutical company.Overshadowed in part by aspirin, introduced into medicine by Heinrich Dreser in 1899, phenacetin was popular for many decades, particularly in widely advertised over-the-counter “headache mixtures,” usually containing phenacetin, an aminopyrine derivative or aspirin, caffeine, and sometimes a barbiturate.
In 1947 David Lester and Leon Greenberg found strong evidence that paracetamol was a major metabolite of acetanilide in human blood, and in a subsequent study they reported that large doses of paracetamol given to albino rats did not cause methemoglobinemia.
It has been suggested that contamination of paracetamol with 4-aminophenol, the substance from which it was synthesized by von Mering, may be the cause for his spurious findings.
In 1953, paracetamol was first marketed in the United States  by Sterling-Winthrop Co.,.
In 1956, 500 mg tablets of paracetamol went on sale in the United Kingdom under the trade name Panadol, produced by Frederick Stearns & Co, a subsidiary of Sterling Drug Inc.
In 1963, paracetamol was added to the British Pharmacopoeia, and has gained popularity since then as an analgesic agent with few side-effects and little interaction with other pharmaceutical agents.
Concerns about paracetamol's safety delayed its widespread acceptance until the 1970s, but in the 1980s paracetamol sales exceeded those of aspirin in many countries, including the United Kingdom.
 

Acetaminophen Specification

The Acetaminophen with CAS registry number of 103-90-2 is also known as Acetamide,N-(4-hydroxyphenyl)-. The IUPAC name is N-(4-Hydroxyphenyl)acetamide. It belongs to product categories of Pharmaceuticals; Aromatic Phenols; Intermediates & Fine Chemicals; Lipid signaling. Its EINECS registry number is 203-157-5. In addition, the formula is C8H9NO2 and the molecular weight is 151.17. This chemical is a white crystalline powder that slightly soluble in water. It may cause damage to health and should be sealed in ventilated, cool room away from fire, heat. What's more, this chemical can be used as antipyretic, analgesic, anti-rheumatic drugs.

Physical properties about Acetaminophen are:
(1)ACD/LogP: 0.48; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): 0.475; (4)ACD/LogD (pH 7.4): 0.474; (5)ACD/BCF (pH 5.5): 1.352; (6)ACD/BCF (pH 7.4): 1.348; (7)ACD/KOC (pH 5.5): 43.194; (8)ACD/KOC (pH 7.4): 43.061; (9)#H bond acceptors: 3; (10)#H bond donors: 2; (11)#Freely Rotating Bonds: 2; (12)Index of Refraction: 1.619; (13)Molar Refractivity: 42.406 cm3; (14)Molar Volume: 120.946 cm3; (15)Surface Tension: 52.801 dyne/cm; (16)Density: 1.25 g/cm3; (17)Flash Point: 188.354 °C; (18)Enthalpy of Vaporization: 66.186 kJ/mol; (19)Boiling Point: 387.831 °C at 760 mmHg; (20)Vapour Pressure: 0 mmHg at 25 °C.

Preparation of Acetaminophen:
Firstly, aminophenol and glacial acetic acid are added into dilute acetic acid by turns. Then the reaction mixture is heated to 150 °C for 7 hours. Secondly, adding acetic anhydride into mixture solution for another 2 hours. At last, product is obtained by rejection filtering, washing and drying. The yield is about 90%.

Uses of Acetaminophen:
It is used to produce N-acetyl-p-vinyloxyaniline by reaction with tetravinylstannane. The reaction occurs with reagents Cu(OAc)2, O2 and solvent acetonitrile at 20 °C for 22 hours. The yield is about 90%.

Paracetamol is used to produce N-acetyl-p-vinyloxyaniline by reaction with tetravinylstannane.

Safety information of Acetaminophen:
When you are using this chemical, please be cautious about it. As a chemical, it is irritating to eyes, respiratory system, skin and is harmful if swallowed. This chemical is also harmful to aquatic organisms that may cause long-term adverse effects in the aquatic environment. However, there is limited evidence of a carcinogenic effect. During using it, wear suitable protective clothing, gloves and eye/face protection. Do not breathe dust and avoid release to the environment. If contact with eyes accidently, rinse immediately with plenty of water and seek medical advice.

You can still convert the following datas into molecular structure:
1. Canonical SMILES: CC(=O)NC1=CC=C(C=C1)O
2. InChI: InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)
3. InChIKey: RZVAJINKPMORJF-UHFFFAOYSA-N

The toxicity data of Acetaminophen is as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
child LDLo oral 50mg/kg (50mg/kg) CARDIAC: OTHER CHANGES

LUNGS, THORAX, OR RESPIRATION: ACUTE PULMONARY EDEMA

KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"
American Journal of Emergency Medicine. Vol. 6, Pg. 510, 1988.
child LDLo oral 140mg/kg/7D-I (140mg/kg) BEHAVIORAL: COMA

LIVER: "HEPATITIS (HEPATOCELLULAR NECROSIS), ZONAL"

BLOOD: "CHANGES IN SERUM COMPOSITION (E.G., TP, BILIRUBIN, CHOLESTEROL)"
Medical Journal of Australia. Vol. 171, Pg. 472, 1999.
child LDLo oral 360mg/kg/2D (360mg/kg) GASTROINTESTINAL: NAUSEA OR VOMITING

LIVER: OTHER CHANGES

SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"
Journal of Pediatrics. Vol. 92, Pg. 832, 1978.
child TDLo oral 591mg/kg/2D-I (591mg/kg) LIVER: LIVER FUNCTION TESTS IMPAIRED

KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"

BLOOD: APLASTIC ANEMIA
Clinical Pediatrics Vol. 33, Pg. 42, 1994.
child TDLo oral 801mg/kg (801mg/kg) BEHAVIORAL: GENERAL ANESTHETIC

GASTROINTESTINAL: NAUSEA OR VOMITING

LIVER: OTHER CHANGES
Pediatrics. Vol. 61, Pg. 68, 1978.
dog LDLo intravenous 826mg/kg (826mg/kg) BEHAVIORAL: ANALGESIA Archives Internationales de Pharmacodynamie et de Therapie. Vol. 149, Pg. 571, 1964.
dog LDLo oral 2gm/kg (2000mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BLOOD: CHANGES IN SPLEEN
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 24, Pg. 602, 1993.
frog LDLo subcutaneous 50mg/kg (50mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES

BEHAVIORAL: ATAXIA
Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 33, Pg. 216, 1894.
guinea pig LD50 oral 2620mg/kg (2620mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: TREMOR

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 47, Pg. 479, 1958.
human LDLo oral 143mg/kg (143mg/kg) BEHAVIORAL: GENERAL ANESTHETIC British Medical Journal. Vol. 282, Pg. 199, 1981.
human LDLo oral 357mg/kg (357mg/kg) BEHAVIORAL: ANOREXIA (HUMAN

GASTROINTESTINAL: NAUSEA OR VOMITING

BEHAVIORAL: COMA
Lancet. Vol. 1, Pg. 66, 1973.
infant TDLo oral 1440mg/kg/6D (1440mg/kg) BEHAVIORAL: IRRITABILITY

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
American Journal of Diseases of Children. Vol. 137, Pg. 386, 1983.
mammal (species unspecified) LD50 unreported 891mg/kg (891mg/kg)   Gigiena i Sanitariya. For English translation, see HYSAAV. Vol. 48(6), Pg. 22, 1983.
mammal (species unspecified) LDLo oral 512mg/kg (512mg/kg)   United States Patent Document. Vol. #4035499,
man LDLo oral 143mg/kg/24H- (143mg/kg) BEHAVIORAL: ANOREXIA (HUMAN

LIVER: "JAUNDICE, OTHER OR UNCLASSIFIED"

LIVER: "HEPATITIS (HEPATOCELLULAR NECROSIS), ZONAL"
American Journal of Medicine. Vol. 74, Pg. 349, 1983.
man LDLo oral 714mg/kg (714mg/kg) LIVER: OTHER CHANGES Human Toxicology. Vol. 1, Pg. 25, 1981.
man TDLo oral 9286ug/kg (9.286mg/kg) SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE

SENSE ORGANS AND SPECIAL SENSES: OTHER: EAR

SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"
Allergy. Vol. 50(Suppl,
man TDLo oral 714mg/kg (714mg/kg) CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE Postgraduate Medical Journal. Vol. 69, Pg. 52, 1993.
mouse LD50 intraperitoneal 367mg/kg (367mg/kg) BEHAVIORAL: ANALGESIA Arzneimittel-Forschung. Drug Research. Vol. 15, Pg. 520, 1965.
mouse LD50 oral 338mg/kg (338mg/kg)   Toxicology and Applied Pharmacology. Vol. 19, Pg. 20, 1971.
mouse LD50 subcutaneous 310mg/kg (310mg/kg)   Human Toxicology. Vol. 3, Pg. 13S, 1984.
pig LDLo intravenous 1gm/kg (1000mg/kg) LIVER: OTHER CHANGES

KIDNEY, URETER, AND BLADDER: OTHER CHANGES
Veterinary and Human Toxicology. Vol. 30, Pg. 324, 1988.
rat LD50 intraperitoneal 1205mg/kg (1205mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: TREMOR
Studi Sassaresi, Sezione 2. Vol. 57, Pg. 561, 1979.
rat LD50 oral 1944mg/kg (1944mg/kg)   United States Patent Document. Vol. #4636513,
women LDLo oral 260mg/kg (260mg/kg) BEHAVIORAL: COMA

GASTROINTESTINAL: NAUSEA OR VOMITING

KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"
JAMA, Journal of the American Medical Association. Vol. 236, Pg. 1874, 1976.
women LDLo oral 400mg/kg (400mg/kg) BEHAVIORAL: COMA

LIVER: LIVER FUNCTION TESTS IMPAIRED
Journal of Toxicology, Clinical Toxicology. Vol. 35, Pg. 325, 1997.
women LDLo oral 650mg/kg (650mg/kg) VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION

VASCULAR: OTHER CHANGES
American Journal of Emergency Medicine. Vol. 6, Pg. 511, 1988.
women TDLo oral 4962ug/kg (4.962mg/kg) GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF ENDOCRINE PANCREAS

BLOOD: OTHER CHANGES

LIVER: LIVER FUNCTION TESTS IMPAIRED
Journal of Toxicology, Clinical Toxicology. Vol. 29, Pg. 223, 1991.
women TDLo oral 13mg/kg (13mg/kg) BEHAVIORAL: EXCITEMENT Allergy. Vol. 50(Suppl,
women TDLo oral 325mg/kg (325mg/kg) BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"

KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"
Postgraduate Medical Journal. Vol. 68, Pg. 116, 1992.
women TDLo oral 490mg/kg (490mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

GASTROINTESTINAL: OTHER CHANGES

KIDNEY, URETER, AND BLADDER: OTHER CHANGES
Southern Medical Journal. Vol. 71, Pg. 906, 1978.

Post buying leads

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View